Trump announces trade deal with EU following months of negotiations
NEW YORK - Pfizer Inc. (NYSE:PFE) announced Wednesday that its board of directors has declared a quarterly cash dividend of $0.43 per share for the third quarter of 2025. The dividend represents an attractive 7.08% yield for the $138 billion pharmaceutical giant, which InvestingPro analysis suggests is currently trading below its Fair Value.
The dividend will be payable on September 2, 2025, to shareholders of record at the close of business on July 25, 2025, according to a company press release.
This marks Pfizer’s 347th consecutive quarterly dividend payment, highlighting the pharmaceutical giant’s long-standing commitment to returning value to shareholders.
Pfizer, a global biopharmaceutical company with a 175-year history, focuses on developing medicines and vaccines across various therapeutic areas. The company operates in both developed and emerging markets worldwide.
The dividend announcement comes as part of Pfizer’s regular quarterly financial activities and represents a continuation of its established dividend policy rather than any change to previous payment levels.
In other recent news, discussions within the Trump administration are focusing on new policies that could impact pharmaceutical advertising in the United States. The potential changes include requiring more detailed disclosures of medication side effects in ads and removing the tax deduction for advertising expenses, which could affect the industry’s $10 billion annual spending. Meanwhile, Jefferies has identified Akero Therapeutics and Scholar Rock as promising targets for mergers and acquisitions in the biotech sector, noting that market stabilization might spur increased deal activity.
In another development, RFK Jr. has reshuffled the Advisory Committee on Immunization Practices, appointing eight new members to replace the previous 17, which could lead to more critical evaluations of vaccine recommendations. BMO Capital analysts have noted potential risks for vaccine manufacturers like Merck and Pfizer/BioNTech due to these changes but expect limited immediate impact on stock prices. Cantor Fitzgerald has maintained a Neutral rating on Pfizer, with a $24 price target, amid evolving vaccine guidelines, particularly concerning its Comirnaty vaccine.
These developments highlight the dynamic nature of the pharmaceutical and biotechnology sectors, with regulatory changes and potential M&A activities being key areas of focus for investors.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.